Breast Oncology

乳腺肿瘤学项目（BOP）由Daniel F. Hayes医学博士和Sofia D. Merajver医学博士共同指导，开展涵盖乳腺癌谱的基础、转化和临床研究。BOP有六个主要的科学主题：1)阐明正常和恶性乳腺组织和细胞调节的分子机制；2)诊断、预后和监测工具的开发；3)开发新的治疗策略；4)评价风险评估和预防策略；5)改善乳腺癌患者的生活质量和生存问题；6)健康服务研究。BOP有来自11个部门的49名成员确保广泛的多学科合作。事实上，在此资助期间，项目成员的397份出版物中，20%是项目内部合作，44%是项目间合作。umbop成员每年获得超过1420万美元的直接同行评审资金，其中400万美元来自NCI。在此期间，BOP研究人员1)对乳腺癌干细胞进行了表征，并开展了化疗加γ分泌酶抑制剂的一期试验；2)进行了临床前研究，并将一种抑制凋亡蛋白抑制剂（lAPs）的新型药物引入临床试验；3)研究RhoC蛋白、癌细胞基质转运、上皮-间质转化、趋化因子介导的转移；4)循环肿瘤细胞的前期和临床研究；5)对乳腺上皮肿瘤发生的转录调控、DNA修复和癌症遗传学的深入了解；6)已确定的涉及MAST和NOTCH基因的易位7)显示出对辅助化疗耐药的内在亚型；8)乳腺癌治疗的药物遗传学研究；9)提高乳腺癌患者的生存率和生活质量。BOP主要致力于卫生服务和成果研究，并对患者的决定进行重要观察。在即将到来的资助期内，BOP将继续进行这些重要的临床前、转化和临床研究，尤其侧重于发现新的诊断和治疗靶点。

The Breast Oncology Program (BOP), co-directed by Daniel F. Hayes, M.D. and Sofia D. Merajver, M.D., conducts basic, translational, and clinical research covering the spectrum of breast cancer. The BOP has six major scientific themes: 1) elucidation of the molecular mechanism of regulation of normal and malignant breast tissues and cells; 2) development of tools for diagnosis, prognosis, and monitoring; 3) development of novel therapeutic strategies; 4) evaluation of risk assessment and prevention strategies; 5) Improvement in quality of life and survivorship issues for patients with breast cancer; and 6) health services research. The BOP has 49 members from 11 Departments within.5 Schools of the University of Michigan, ensuring broad multi-disciplinary collaborations. Indeed, of the 397 publications by program members over this grant period, 20% were Intra-programmatic and 44% were inter-programmatic collaborations. Members of the UM BOP receive over $14,2 million In annual direct peer-reviewed funding of which $4 million Is from the NCI. During this period, BOP investigators have 1) characterized the breast cancer stem cell and conducted a phase 1 trial of chemotherapy plus a gamma secretase Inhibitor, 2) performed pre-clinical studies and Introduced a novel agent that inhibits the inhibitor of apoptosis proteins (lAPs) into clinical trial; 3) studied RhoC proteins, cancer cell matrix transport, epithelial-mesenchymal transition, and chemokine mediation of metastasis; 4) performed pre- and clinical studies of circulating tumor cells; 5) advanced understanding of transcriptional regulation, DNA repair, and cancer genetics, of breast epithelial tumorigenesis; 6) Identified translocations involving the MAST and NOTCH genes 7) demonstrated intrinsic subtypes that are resistant to adjuvant chemotherapy; 8) Investigated pharmacogenetics of breast cancer treatment; and 9) furthered the breast cancer survivorship and quality of life. The BOP has a major commitment to health services and outcomes research, with Important observations regarding patient decision. The BOP will continue these important pre-clinical, translational, and clinical studies in the upcoming funding period, particularly focusing on discovery of new diagnostic and therapeutic targets.